330796-48-0

Basic information

• Product Name: 4-(4-METHYL-PIPERAZIN-1-YL)-3-TRIFLUOROMETHYL-PHENYLAMINE
• Synonyms: 4-(4-METHYL-PIPERAZIN-1-YL)-3-TRIFLUOROMETHYL-PHENYLAMINE;TIMTEC-BB SBB012041;4-(4-METHYLPIPERAZIN-1-YL)-3-(TRIFLUOROMETHYL)ANILINE
• CAS NO: 330796-48-0
• Molecular Formula: C12H16F3N3
• Molecular Weight: 259.27
• Mol File: 330796-48-0.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 356.5°C at 760 mmHg
• Flash Point: 169.4°C
• Appearance: /
• Density: 1.243g/cm³
• Vapor Pressure: 2.91E-05mmHg at 25°C
• Refractive Index: 1.525
• CAS DataBase Reference: 4-(4-METHYL-PIPERAZIN-1-YL)-3-TRIFLUOROMETHYL-PHENYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-METHYL-PIPERAZIN-1-YL)-3-TRIFLUOROMETHYL-PHENYLAMINE(330796-48-0)
• EPA Substance Registry System: 4-(4-METHYL-PIPERAZIN-1-YL)-3-TRIFLUOROMETHYL-PHENYLAMINE(330796-48-0)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 330796-48-0(Hazardous Substances Data)

Usage

Description

4-(4-METHYL-PIPERAZIN-1-YL)-3-TRIFLUOROMETHYL-PHENYLAMINE is an organic compound with the molecular formula C11H16F3N3. It is a derivative of phenylamine, featuring a trifluoromethyl group and a 4-methylpiperazine ring. 4-(4-METHYL-PIPERAZIN-1-YL)-3-TRIFLUOROMETHYL-PHENYLAMINE is known for its potential applications in the synthesis of various chemical and pharmaceutical products due to its unique structural features.

Uses

Used in Pharmaceutical Industry:
4-(4-METHYL-PIPERAZIN-1-YL)-3-TRIFLUOROMETHYL-PHENYLAMINE is used as a key intermediate in the synthesis of heterocycle-fused pyrimidine derivatives. These derivatives have potential applications in the development of new drugs and therapeutic agents, particularly in the treatment of various diseases and medical conditions.
Used in Chemical Synthesis:
In the field of organic chemistry, 4-(4-METHYL-PIPERAZIN-1-YL)-3-TRIFLUOROMETHYL-PHENYLAMINE serves as a valuable building block for the creation of more complex molecular structures. Its unique combination of functional groups allows for further chemical reactions and modifications, leading to the development of novel compounds with diverse properties and applications.

InChI:InChI=1/C12H16F3N3/c1-17-4-6-18(7-5-17)11-3-2-9(16)8-10(11)12(13,14)15/h2-3,8H,4-7,16H2,1H3

Upstream product

• 109-01-3 1-methyl-piperazine 
• 400-74-8 2-Fluoro-5-nitrobenzotrifluoride 
• 367-67-9 2-bromo-5-nitro-benzotrifluoride 
• 309734-66-5 1-methyl-4-(4-nitro-2-(trifluoromethyl)phenyl)piperazine 

Relevant articles and documents

NOVEL CONFORMATIONALLY-RESTRICTED ANALOGUES OF SORAFENIB AND REGORAFENIB AS SELECTIVE KINASE INHIBITORS FOR CANCER TREATMENT

Novel conformationally-restricted analogues of sorafenib and regorafenib as selective kinase inhibitors for therapeutic formulations and methods for treating cancer.

Discovery of potent Pan-Raf inhibitors with increased solubility to overcome drug resistance

Despite various applications of kinase inhibitors in oncology and inflammatory diseases, the emergence of resistance still remains the major barrier to achieve long-term remission in cancer treatment. With the aim of overcoming the resistance induced by type IIB BRaf V600E selective inhibitor vemurafenib, and further ameliorating the antiproliferative activity, a novel type IIA Pan-Raf inhibitors Ia–Io based on pyrrolo[2,3-d] pyrimidine scaffold were designed and evaluated in this work. Herein, we tried to improve the cellular potency of the target compounds by increasing their solubility. Among them, Il, with the solubility of 0.107 mg/mL, demonstrated favorable cellular activity against vemurafenib-resistant carcinoma cells including BRafWT phenotypic melanoma SK-MEL-2 and BRafV600E phenotypic colorectal cancer HT-29 cell lines. Based on the well solubility, Il exhibited good metabolic stability compared to sorafenib and showed favorable pharmacokinetic profiles in rats. As for the biological mechanism research, Il had the similar P-ERK kinase inhibitory activity in A375 and SK-Mel-2 cells as our previously lead P-2. Il may become a good candidate compound to overcome the resistance associated with vemurafenib.

Design, synthesis and evaluation of derivatives based on pyrimidine scaffold as potent Pan-Raf inhibitors to overcome resistance

Simutaneous targeting all Raf isoforms offers the prospect of enhanced efficacy as well as reduced potential for resistance. Described herein is the discovery and characterization of a series of pyrimidine scaffold with DFG-out conformation as potent Pan-Raf inhibitors. Among them, I-41 with excellent Pan-Raf potency demonstrates inhibitory activity against BRafWTphenotypic melanoma and BRafV600Ephenotypic colon cells. The western blot results for the Erk inhibition in human melanoma SK-Mel-2?cell lines showed I-41 inhibited the proliferation of SK-Mel-2?cell lines without paradoxical activation of Erk, which supported I-41 may become a good candidate compound to overcome the resistance of melanoma against the current BRafV600Einhibitor therapy. I-41 also have a favorable pharmacokinetic profile in rat. Synthesis, SAR, lead selection, and evaluation of the key compounds studies are described.